{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Angiogenesis > NaquotinibCAS：1448232-80-1
Molecular Formula：C30H42N8O3
Molecular Weight：562.71
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Solid
Qty：
Size：
| CAS | 1448232-80-1 |
| Name | Naquotinib |
| Molecular Formula | C30H42N8O3 |
| Molecular Weight | 562.71 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD30496701 |
| SMILES | O=C(C1=NC(CC)=C(O[C@H]2CN(C(C=C)=O)CC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)N |
| Target Point | EGFR |
| Passage | Angiogenesis;Protein Tyrosine Kinase/RTK; JAK/STAT Signaling |
| Background | Naquotinib is an irreversible, mutant-selective epidermal growth factor receptor (EGFR) inhibitor |
| Biological Activity | Naquotinib (ASP8273)是一种具有口服活性的、不可逆的、对突变体具有选择性的epidermal growth factor receptor (EGFR)抑制剂，具有潜在的抗肿瘤活性。[1-2] |
| In Vitro | ASP8273是一种不可逆的TKI小分子抑制剂，抑制EGFR突变体包括T97M的激酶活性，而对野生型EGFR的活性有限。在体外酶活性和细胞实验中，ASP8273与EGFR突变体(L858R/T790M)通过半胱氨酸残基共价结合，长效抑制EGFR的磷酸化24小时。在具有上述EGFR突变的NSCLC细胞系中，ASP8273对EGFR突变体的IC50值在8-33 nM 范围间，比对WT EGFR更有效(对WT EGFR的IC50为230 nM)。ASP8273还能通过ERK和Akt抑制信号通路。在对耐其他EGFR TKIs如AZD9291和CO-1686的突变EGFR细胞系张，ASP8273具有活性[1-2]。 |
| In Vivo | 在小鼠肿瘤异种移植研究中，给NCI-H1975(L858R/T790M)，HCC827(del ex19)and PC-9(del ex19)异种移植小鼠予以重复的口服给药，ASP8273能以剂量依赖方式诱导肿瘤消退。给药方案并不影响ASP8273的效力。在HCC827和NCI-H1975模型中，10，30，100mg/kg的ASP8273可诱导肿瘤消退，而不影响其体重。在NSCLC患者肿瘤源性的异种移植模型(抑制了表达T790M/L858R的LU1868)中，10 mg/kg以上的ASP8273将产生肿瘤生长抑制；另一方面，10 和30mg/kg ASP8273在A431异种移植的模型中没有显著的肿瘤生长抑制作用[1-2]。 |
| Cell Experiment | In HCC827 and NCI-H1975 xenograft models，ASP8273 induced tumor regression at 10，30 and 100mg/kg without affecting body weight. ASP8273 also produced tumor growth inhibition from 10mg/kg in the NSCLC patient derived tumor xenograft，LU1868 which express T790M/L858R.[2] |
| Animal Experiment | ASP8273 selectively inhibited phosphorylation of EGFR and its down-stream signal pathway，ERK and Akt from 10nM in HCC827 and NCI-H1975 while inhibitory effects were only detected at 1000nM in A431.In NCI-H1650(del ex19)，ASP8273 inhibited cell growth with an IC50 value of 70nM while other EGFR-TKIs were only partially effective. ERK and Akt phosphorylation were diminished after ASP8273 treatment at 1000nM，however，other EGFR-TKIs only partially reduced the phosphorylation levels of these proteins. ASP8273 potently enhanced the caspase activity in NCI-H1650 after 24h treatment，which is concordant with signal and cell growth inhibitory effect.[2] |
| Data Literature Source | [1] Sakagami H，et al. Cancer Res. 2014，74(19 Supplement):1728. [2] Konagai S，et al. Cancer Res. 2015，75(15 Supplement):2586. |
| Unit | Bottle |
| Specification | 5mg |
Naquotinib是一种不可逆的、对突变体具有选择性的epidermal growth factor receptor (EGFR)抑制剂
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
